Abrocitinib 50 mg, 100 mg, 200 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 50 mg, 100 mg, 200 mg

Reference Brands: Cibinqo (USA/EU)

Category: Immune Disorder

Abrocitinib is an oral Janus kinase (JAK1) inhibitor used for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and adolescents. It works by blocking JAK1-mediated cytokine signaling, reducing inflammation, itching, and redness associated with eczema. The drug provides a targeted immune-modulating approach with faster symptom relief compared to conventional immunosuppressants.

Product Description:

Abrocitinib is an oral inhibitor selective for Janus kinase 1. JAK1 carries the signal from interleukin-4, interleukin-13, interleukin-31 and thymic stromal lymphopoietin — the cytokines that drive the inflammation, barrier breakdown and itch of atopic dermatitis. Blocking one kinase rather than several is intended to give a wide effect on the disease with less of the haematological disturbance that comes from JAK2 blockade.

It is used for moderate to severe atopic dermatitis in adults and adolescents whose disease is not controlled by topical treatment. Its distinguishing feature is speed: itch improves within days, faster than the biologics, which matters in a disease where sleep loss from itch is often the worst symptom. Against that, it carries the oral JAK class warnings — serious infection, tuberculosis reactivation, herpes zoster, thrombosis, cardiovascular events and malignancy — with screening before treatment and blood count, lipid and liver monitoring during it. Live vaccines are avoided.

Sourcing notes. Originator product, on patent, no generic. Registered in the US, EU and many other markets. Supply is through authorised distribution. Because it competes directly with injectable biologics, formulary position and the local view of JAK safety determine volume more than price.